Skip to main content

Advertisement

Table 4 Drug Exposure

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

  Cilengitide + Gemcitabine n = 44 Gemcitabine n = 42
  Cilengitide Gemcitabine Gemcitabine
Mean duration ± SD, days 134 ± 89 120 ± 75
Median duration (range), days 133 (1–344) 135 (1–330)
Mean no. cycles ± SD 4.8 ± 4.0 4.1 ± 2.7
Median no. cycles (range) 4.5 (0–19) 4.5 (1–12)
Mean RDI ± SD 1st 6 mths (range), % 93 ± 11 94 ± 11 89 ± 15
Median RDI 1st 6 mths (range), % 97 (53–101) 99 (55–104) 96 (47–105)
  1. Abbreviations: SD, standard deviation; RDI, relative dose intensity; mths, months.
  2. RDI = % of planned total dosage